SCHEMBL2634843

SCHEMBL2634843

CN1CCN(C2CCN(c3ccc(Br)cc3)CC2)CC1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 10/20 0.58
L3MBTL1 Q9Y468 10/20 0.58
MBTD1 Q05BQ5 3/20 0.49
KMT2A Q03164 2/20 0.47
TP53BP1 Q12888 2/20 0.47
ALDH1A1 P00352 2/20 0.46
GRIN2B Q13224 1/20 0.45
PIM1 P11309 1/20 0.45
KDM4E B2RXH2 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
ADRA2C P18825 1/20 0.44
GFER P55789 1/20 0.44
PTK2B Q14289 1/20 0.44
ESR2 Q92731 1/20 0.44
VCP P55072 1/20 0.44
L3MBTL4 Q8NA19 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28506443 0.93 L3MBTL3 (0.53) L3MBTL3L3MBTL1MBTD1KMT2ATP53BP1
SCHEMBL13616253 0.85 L3MBTL3 (0.59) L3MBTL3L3MBTL1MBTD1KMT2ATP53BP1
SCHEMBL29104019 0.84 L3MBTL3 (0.81) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL2155939 0.84 L3MBTL3 (0.57) L3MBTL3L3MBTL1MBTD1KMT2AALDH1A1
SCHEMBL24596956 0.83 L3MBTL3 (0.58) L3MBTL3L3MBTL1MBTD1KMT2ATP53BP1
SCHEMBL156422 0.83 ALDH1A1 (0.68) L3MBTL3L3MBTL1MBTD1KMT2ATP53BP1
SCHEMBL3523735 0.83 L3MBTL3 (0.79) L3MBTL3L3MBTL1MBTD1TP53BP1ALDH1A1
SCHEMBL28330181 0.83 L3MBTL1 (0.71) L3MBTL3L3MBTL1MBTD1ALDH1A1GRIN2B
SCHEMBL19402 0.82 ALDH1A1 (0.63) KMT2AALDH1A1KDM4EGAAMAPT
SCHEMBL2635187 0.81 VCP (0.58) L3MBTL3L3MBTL1MBTD1TP53BP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633173-B2 Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives CEPHALON, INC (US) 2014-01-21 US disclosed
US-20130296312-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives CEPHALON, INC. 2013-11-07 US disclosed
US-8501936-B2 Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives CEPHALON, INC. (US) 2013-08-06 US disclosed
CN-102459258-A Preparation and use of 1,2, 4-triazolo [1,5a ] pyridine derivatives CEPHALON INC 2012-05-16 CN disclosed
EP-2438066-A2 PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES Cephalon, Inc. (US) 2012-04-11 EP disclosed
US-20100311693-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives CEPHALON, INC. (US) 2010-12-09 US disclosed
WO-2010141796-A2 PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES CEPHALON, INC. (US) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296312-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives JAK2, JAK1, JAK3 L3MBTL3 3730/4885L3MBTL1 2931/4885MBTD1 4106/4885
US-20100311693-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives CCNA1, CCNY, RB1 L3MBTL3 3771/4885L3MBTL1 3256/4885MBTD1 4397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.